AGIOS PHARMACEUTICALS, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- AGIOS PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2021-09-30 was $254.39M.
- AGIOS PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2021-06-30 was $529.05M.
- AGIOS PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for fiscal 2021 was $802.49M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2021-12-31 | $802.49M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $254.39M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $529.05M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |